Abstract
Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39%) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14%) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40% of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 355-359 |
| Number of pages | 5 |
| Journal | AIDS |
| Volume | 7 |
| Issue number | 3 |
| State | Published - Mar 1993 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cross-reactivity
- Dapsone
- HIV
- Intolerance
- Pneumocystis carinii
- Trimethoprim-sulfamethoxazole
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS